These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 12411300)

  • 1. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.
    Cortes J; Albitar M; Thomas D; Giles F; Kurzrock R; Thibault A; Rackoff W; Koller C; O'Brien S; Garcia-Manero G; Talpaz M; Kantarjian H
    Blood; 2003 Mar; 101(5):1692-7. PubMed ID: 12411300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.
    Zujewski J; Horak ID; Bol CJ; Woestenborghs R; Bowden C; End DW; Piotrovsky VK; Chiao J; Belly RT; Todd A; Kopp WC; Kohler DR; Chow C; Noone M; Hakim FT; Larkin G; Gress RE; Nussenblatt RB; Kremer AB; Cowan KH
    J Clin Oncol; 2000 Feb; 18(4):927-41. PubMed ID: 10673536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.
    Karp JE; Lancet JE; Kaufmann SH; End DW; Wright JJ; Bol K; Horak I; Tidwell ML; Liesveld J; Kottke TJ; Ange D; Buddharaju L; Gojo I; Highsmith WE; Belly RT; Hohl RJ; Rybak ME; Thibault A; Rosenblatt J
    Blood; 2001 Jun; 97(11):3361-9. PubMed ID: 11369625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors.
    Punt CJ; van Maanen L; Bol CJ; Seifert WF; Wagener DJ
    Anticancer Drugs; 2001 Mar; 12(3):193-7. PubMed ID: 11290865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.
    Kurzrock R; Albitar M; Cortes JE; Estey EH; Faderl SH; Garcia-Manero G; Thomas DA; Giles FJ; Ryback ME; Thibault A; De Porre P; Kantarjian HM
    J Clin Oncol; 2004 Apr; 22(7):1287-92. PubMed ID: 15051776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies.
    Karp JE
    Semin Hematol; 2001 Jul; 38(3 Suppl 7):16-23. PubMed ID: 11523024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.
    Crul M; de Klerk GJ; Swart M; van't Veer LJ; de Jong D; Boerrigter L; Palmer PA; Bol CJ; Tan H; de Gast GC; Beijnen JH; Schellens JH
    J Clin Oncol; 2002 Jun; 20(11):2726-35. PubMed ID: 12039935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.
    Kurzrock R; Kantarjian HM; Cortes JE; Singhania N; Thomas DA; Wilson EF; Wright JJ; Freireich EJ; Talpaz M; Sebti SM
    Blood; 2003 Dec; 102(13):4527-34. PubMed ID: 12947010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.
    Adjei AA; Croghan GA; Erlichman C; Marks RS; Reid JM; Sloan JA; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Bruzek LM; Atherton P; Thibault A; Palmer PA; Kaufmann SH
    Clin Cancer Res; 2003 Jul; 9(7):2520-6. PubMed ID: 12855626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia.
    Mesa RA; Tefferi A; Gray LA; Reeder T; Schroeder G; Kaufmann SH
    Leukemia; 2003 May; 17(5):849-55. PubMed ID: 12750696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells.
    Le Gouill S; Pellat-Deceunynck C; Harousseau JL; Rapp MJ; Robillard N; Bataille R; Amiot M
    Leukemia; 2002 Sep; 16(9):1664-7. PubMed ID: 12200678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
    Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
    Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.
    Cohen SJ; Ho L; Ranganathan S; Abbruzzese JL; Alpaugh RK; Beard M; Lewis NL; McLaughlin S; Rogatko A; Perez-Ruixo JJ; Thistle AM; Verhaeghe T; Wang H; Weiner LM; Wright JJ; Hudes GR; Meropol NJ
    J Clin Oncol; 2003 Apr; 21(7):1301-6. PubMed ID: 12663718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma.
    Rosenberg JE; von der Maase H; Seigne JD; Mardiak J; Vaughn DJ; Moore M; Sahasrabudhe D; Palmer PA; Perez-Ruixo JJ; Small EJ
    Cancer; 2005 May; 103(10):2035-41. PubMed ID: 15812833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer.
    Cohen SJ; Gallo J; Lewis NL; Alpaugh RK; Gentner L; Rogatko A; Yeslow G; Schol J; Verhaeghe T; Zannikos P; Palmer PA; Weiner LM; Meropol NJ
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):513-8. PubMed ID: 14760509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multifaceted approach to the treatment of bcr-abl-positive leukemias.
    O'Dwyer M
    Oncologist; 2002; 7 Suppl 1():30-8. PubMed ID: 11961207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer.
    Adjei AA; Mauer A; Bruzek L; Marks RS; Hillman S; Geyer S; Hanson LJ; Wright JJ; Erlichman C; Kaufmann SH; Vokes EE
    J Clin Oncol; 2003 May; 21(9):1760-6. PubMed ID: 12721252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy.
    Borthakur G; Kantarjian H; Daley G; Talpaz M; O'Brien S; Garcia-Manero G; Giles F; Faderl S; Sugrue M; Cortes J
    Cancer; 2006 Jan; 106(2):346-52. PubMed ID: 16342165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. G-CSF for imatinib-induced neutropenia.
    Heim D; Ebnöther M; Meyer-Monard S; Tsakiris D; Linn M; Tichelli A; Gratwohl A
    Leukemia; 2003 Apr; 17(4):805-7. PubMed ID: 12682643
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.